Orbiter-tension of Hormone Therapy After Menopause (which twice defers to “see tension” on the CHD and mortality rows — this is that tension). The same question — does starting HRT earlier (age <60, or <10 y from menopause) change its effect on CHD and all-cause mortality? — is answered oppositely by two gold guideline families reading a largely shared trial base. It is the guidance-null defeated by showing why they disagree, not by picking a side.
(inferred from 2022 Hormone Therapy Position Statement Advisory Panel of The North American Menopause Society, 2022; National Institute for Health and Care Excellence, 2024)
The two positions on the same subgroups
View A — NAMS 2022 endorses the window. Younger initiation is associated with lower CHD and mortality:
«A 2019 systematic review and meta-regression analysis of RCTs that examined the timing hypothesis of hormone therapy compared with controls or nonusers of hormone therapy found that younger hormone therapy initiation (participants aged <60 y) was associated with lower odds of CHD (OR, 0.61; 95% CI, 0.37-1.00), all-cause mortality (OR, 0.72; 95% CI, 0.57-0.91), and cardiac mortality (OR, 0.61; 95% CI, 0.37-1.00)» (2022 Hormone Therapy Position Statement Advisory Panel of The North American Menopause Society, 2022)
And in the WHI 50-59 subgroup specifically: «all-cause mortality was significantly reduced in the pooled trials versus placebo (HR, 0.69; 95% CI, 0.51-0.94)» (2022 Hormone Therapy Position Statement Advisory Panel of The North American Menopause Society, 2022).
View B — NICE NG23 2024 declines it. The same subgroup signal does not survive its appraisal:
«A decrease in all-cause mortality was reported for 1 isolated subgroup (women starting oestrogen-only HRT aged between 50 and 59). In isolation, this was a statistically significant figure. But in a wider context, it cannot be interpreted as good evidence of a different effect in this group.» (National Institute for Health and Care Excellence, 2024)
«In what little data was available, the risk did not have a clear tendency to decrease or increase with either of the above 2 factors (that is, with the age of the person when they start HRT or the time between a person’s menopause and when they start HRT).» (National Institute for Health and Care Excellence, 2024)
NICE’s operative recommendation: «taking either combined HRT or oestrogen-only HRT is unlikely to affect life expectancy» (National Institute for Health and Care Excellence, 2024).
Counter-passage — is the issue joined?
Checked NAMS’s own text: the window rests substantially on evidence NICE excludes, and NAMS itself records the fragility:
«the results for CHD, cardiac mortality, and all-cause mortality were all attenuated after excluding open-label trials in which the knowledge of active treatment may affect treatment options and outcomes.» (2022 Hormone Therapy Position Statement Advisory Panel of The North American Menopause Society, 2022)
So the divergence is partly a different evidence base (NICE restricts to RCTs for mortality; NAMS admits observational + open-label + meta-regression + WHI subgroups) and partly a genuine disagreement on the same WHI subgroups (significant-in-isolation vs chance). It is not a fake tension of different scopes — both answer does starting earlier change the CV/mortality outcome? on overlapping data. Guidance-difference reasons 2 (different evidence base) and 3 (genuine disagreement) both fire; reason 5 (process defect) does not — both bodies apply a stated appraisal method, and NICE’s RCT-restriction is a defensible choice, not a lapse -> Certainty of Evidence vs Strength of Recommendation.
Hidden insight — the window rides on the weakest evidence in the stack
The critical-window hypothesis is carried by the softer evidence (observational, open-label, a non-significant RCT-subgroup trend). A body that weights RCT evidence hardest will not endorse it; a body that admits the wider evidence will. This is the telos’s case where guidance families disagree because the evidence does not determine the answer — and the same discipline that governs a U/J-shaped protective arm applies to a subgroup signal: a 50-59 mortality benefit «significant in isolation» that shows no age gradient is a candidate artifact, not an established effect modifier -> The U-Shaped Association Artifact. The NAMS-endorsed magnitudes are real point estimates; what is contested is whether they are effect modification (route (b)) or noise.
Decision relevance
- The disputed part is a bonus, not the core decision. Both bodies agree HRT does not raise all-cause mortality overall, and both support it for vasomotor symptoms and bone in a symptomatic woman <60 / <10 y from menopause. So the timing dispute is over a possible CV/mortality benefit (NAMS) vs no effect (NICE) — the symptom-relief-and-bone decision stands either way -> Hormone Therapy After Menopause.
- The harm side moves with timing regardless of the CV dispute (agreed): starting >60 / >10 y raises absolute CHD/stroke/VTE/dementia risk. So late initiation is worse whether or not early initiation helps — a route-(a) baseline-risk fact independent of the contested effect modification -> Baseline Risk and the Relative-Absolute Split.
- Do not report a life-expectancy benefit from early HRT as established. The honest statement is: HRT is
a symptom-and-bone treatment; a cardioprotective early-initiation benefit is a live, unresolved hypothesis
carried by the weaker evidence, and confidence on it stays
low. A dedicated RCT of early-initiation hard outcomes would resolve it. - Which non-health objective moved either body’s framing is not visible here -> Which Objective Moved This Recommendation (noted, not charged).